Showing 3611-3620 of 4073 results for "".
- University of Arkansas Researcher Scores $1.6M NIH Grant for Research on Chronic Skin Woundshttps://practicaldermatology.com/news/puniversity-of-arkansas-researcher-scores-16m-nih-grant-for-research-on-chronic-skin-wounds/2460976/University of Arkansas biomedical engineering professor Kyle Quinn received a four-year, $1.6 million grant from the National Institutes of Health to develop non-invasive, real-time “optical biopsies” of chronic skin wounds. The goal is to provide digital histopathology imag
- Dupixent Reduces Itch, Clears Skin in Prurigo Nodularis Phase 3 Trialhttps://practicaldermatology.com/news/dupixent-reduces-itch-clears-skin-in-prurigo-nodularis-phase-3-trial/2460969/Data from a pivotal Phase 3 trial show that Dupixent® (dupilumab) reduced itch and led to higher rates of skin clearance than placebo among adults with uncontrolled prurigo nodularis. In the Phase 3 PRIME2 trial, 37 percent of Dupixent
- Mount Sinai Awarded $4 Million Grant to Launch Skin Biology and Diseases Resource-based Centerhttps://practicaldermatology.com/news/mount-sinai-awarded-4-million-grant-to-launch-skin-biology-and-diseases-resource-based-center/2460963/The Icahn School of Medicine at Mount Sinai is establishing a Skin Biology and Diseases Resource-based Center (SBDRC), funded by a $4 million, five-year P30 grant from the National Institutes of Health and the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS).
- Topline Phase 2b Data Promising for Timber's Topical Isotretinoin in CIhttps://practicaldermatology.com/news/topline-phase-2b-data-promising-for-timbers-topical-isotretinoin-in-ci/2460946/Top-line data from Timber Pharmaceuticals’ Phase 2b CONTROL study show “clinically meaningful efficacy with a favorable safety profile” for investigational topical isotretinoin, says the company’s Chairman and CEO John Koconis. TMB-001 is formulated using
- Amgen/Kyowa Kirin's Anti-OX40 Shows Efficacy in Phase 2 for ADhttps://practicaldermatology.com/news/amgenkyowa-kirins-anti-ox40-shows-efficacy-in-phase-2-for-ad/2460943/Positive data from a Phase 2 study of AMG 451/KHK4083, presented at the European Academy of Dermatology and Venereology 30th Virtual Congress, show that the potential first-in-class anti-OX40 fully human monoclonal antibody in development for the treatment of moderate-to-severe atopic d
- Long-term Extension Study Confirms Benefits of Topical Tapinarof in Psoriasishttps://practicaldermatology.com/news/long-term-extension-study-confirms-benefits-of-topical-tapinarof-in-ad/2460936/Final results from the Phase 3 PSOARING 3 long-term extension study show that Dermavant’s investigational tapinarof 1%, once daily, non-steroidal topical cream for the treatment of plaque psoriasis in adults was well tolerated long term, with a safety
- Data Show Continuous Response to LEO's Tralokinumab in Adults with ADhttps://practicaldermatology.com/news/data-show-continuous-response-to-leos-tralokinumab-in-adults-with-ad/2460933/After two years of continuous treatment with tralokinumab, adult patients with moderate-to-severe atopic dermatitis maintained improvements in signs and symptoms, itch severity, and sleep interference, according to interim findings from the Phase 3 ECZTEND trial presented as an oral presenta
- Bimekizumab Performs Well in Psoriasis with Results Lasting through Two Yearshttps://practicaldermatology.com/news/bimekizumab-performs-well-in-psoriasis-with-results-lasting-through-two-years/2460929/Interim results from the BE BRIGHT open-label extension (OLE) study showed clinical responses observed in bimekizumab-treated psoriasis patients during the first 16 weeks of BE SURE were sustained through to two years of treatment with continuous maintenance dosing, UCB reports. T
- Mayne Pharma's Lexette Approved for Adolescentshttps://practicaldermatology.com/news/mayne-pharmas-lexette-approved-for-adolescents/2460921/Lexette® (halobetasol propionate) foam, 0.05% from Mayne Pharma is now approved for the treatment of plaque psoriasis in patients aged 12 years and older. FDA approved Lexette in 2018 for use in adults. Approval in adolescents is
- Cytrellis Secures New Round of Fundinghttps://practicaldermatology.com/news/cytrellis-secures-new-round-of-funding/2460920/Cytrellis has closed a $50 million Series C funding round. The financing was led by D1 Capital Partners and included participation from an additional new investor, Sands Capital, as well as existing institutional investors, ARCH Venture Partners and PFM Health Sciences. Proceeds will be